For future study that may address further the remission effect of STII therapy in newly diagnosed T2DM patients, sequential treatment with incretin-related agent (GLP-1RA and dipeptidyl peptidase- 4 (DPP- 4) inhibitors22 or the sodium-glucose cotransporter 2 (SGLT2) inhibitor23, actively compared with metformin or placebo, should be explored. Here, SLC5A2 is linked to type 2 diabetes mellitus.